首页> 外国专利> THYMOSIN ALPHA PEPTIDE FOR PREVENTING, REDUCING THE SEVERITY OF, AND TREATING INFECTION

THYMOSIN ALPHA PEPTIDE FOR PREVENTING, REDUCING THE SEVERITY OF, AND TREATING INFECTION

机译:胸腺肽α肽,用于预防,减少感染的严重性和治疗感染

摘要

The present invention provides methods for preventing, treating, or reducing the severity of infection, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen, so as to prime or enhance a patient's immune response for pathogen exposure. In certain embodiments, the alpha thymosin regimen is scheduled or timed with respect to potential or expected pathogen exposures. The regimen of alpha thymosin peptide as described herein provides the patient with a more robust immune response to pathogen exposure, including higher antibody titers and/or a more rapid antibody response. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of nosocomial infection or illness.
机译:本发明提供了预防,治疗或减轻感染严重程度的方法,包括细菌,病毒和真菌感染,以及病因更为复杂的感染。本发明涉及α胸腺素肽方案的施用,以引发或增强患者针对病原体暴露的免疫应答。在某些实施方案中,关于潜在或预期的病原体暴露来计划或定时α胸腺素方案。如本文所述的α胸腺素肽的方案为患者提供了对病原体暴露的更强壮的免疫应答,包括更高的抗体滴度和/或更快速的抗体应答。在某些实施方案中,患者是免疫缺陷的或免疫受损的,和/或患者是住院的或计划住院的,使得α胸腺肽肽的方案有助于保护患者免受医院感染或疾病的严重性或减轻其严重性。

著录项

  • 公开/公告号EP2675272A1

    专利类型

  • 公开/公告日2013-12-25

    原文格式PDF

  • 申请/专利权人 SCICLONE PHARMACEUTICALS INC.;

    申请/专利号EP20120744727

  • 发明设计人 TUTHILL CYNTHIA;

    申请日2012-02-03

  • 分类号A01N25;

  • 国家 EP

  • 入库时间 2022-08-21 15:47:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号